Trialing plasma protein therapies for rare disorders: Thinking outside the box

Pharmaceuticals Policy and Law

Volumn 11, Issue 4, 2009, Pages 345-352

  Farrugia, Albert ^a,b  

^a University of Western Australia ^*  (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013566651     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: 10.3233/PPL-2009-0230     Document Type: Article

References (24)

1. J.M. Boyle and R.H. Buckley, Population prevalence of diagnosed primary immunodeficiency diseases in the United States, J Clin Immunol 27(5) (Sep 2007), 497-502.
2. R.A. Schwartz, R.M. Modak and P. Modak, Common. Variable Immunodeficiency. On http:// emedicine.medscape.com/article/1051103-overview. Accessed on 1 March 2009.
3. P.H.B. Bolton-Maggs, Factor XI deficiency. Treatment of hemophilia June 2004 NO 16. On www.wfh.org Accessed on 1 March 2009.
4. M.P. Kaczor, M. Sanak, M. Libura-Twardowska and A. Szczeklik, The prevalence of alpha(1)-antitrypsin deficiency in a representative population sample from Poland, Respir Med 101(12) (Dec 2007), 2520-2525.
5. B.S. Schoenberg, Epidemiology of Guillain-Barré syndrome, Adv Neurol 19 (1978), 249-260.
6. A. Lavandeira, Orphan drugs: legal aspects, current situation, Haemophilia 8 (2002), 194-198.
7. R. Joppi, V. Bertele and S. Garattini, Orphan drug development is progressing too slowly, Br J Clin Pharmacol 61(3), 355-360.
8. P. Walton, Factors Impacting Industry’s Ability to Bring New (Rare Diseases) Biotherapies to Patients. Presented to the Food and Drug Administration Workshop on Rare Disorders. On http://www.fda.gov/cber/minutes/biother061305t.htm. Accessed on 1 March 2009.
9. A. Gibbons, Billion-dollar orphans: prescription for trouble, Science (1990).
10. J.K. Aronson, Rare diseases and orphan drugs, Br J Clin Pharmacol 61(3), 243-245.
11. E. Seoane-Vazquez, R. Rodriguez-Monguio, S.L. Szeinbach and J. Visaria, Incentives for orphan drug research and development in the United, States Orphanet Journal of Rare Diseases 3(33) (2008), doi: 10.1186/1750-1172-3-33.
12. EMEA. List of orphan-designated authorised medicines. On www.emea.europa.eupdfshumancomp 56357508en.pdf. Accessed on 1 March 2009.
13. B. Wilcken, Rare diseases and the assessment of intervention: What sorts of clinical trials can we use? J Inherit Metab Dis 24 (2001), 291-298.
14. J.H. Evans and S.T. Ildstad, eds, Small Clinical Trials: Issues and Challenges. National Academy of Sciences 2001. On http://www.nap.edu/catalog/10078.html. Accessed on 1 March 2009.
15. R.J. Lilford, J.G. Thornton and D. Braunholtz, Clinical trials and rare diseases: a way out of a conundrum, BMJ 311 (1995), 1621-1625.
16. S.-B. Tan, K.B.G. Dear, P. Bruzzi and D. Machin, Strategy for randomised clinical trials in rare cancers, BMJ 327 (2003), 47-49.
17. S. Pocock and D.J. Spiegelhalter, Domiciliary thrombolysis by general practitioners, BMJ 305 (1992), 1015.
18. S. Goodman, Incorporating information from adults into pediatric trial design: A Case Study of Guillan-Barré Syndrome. Presented to the FDA Workshop Bayes workshop on 20 May 2004, On www. Accessed on 1 March 2009.
19. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates, Haemophilia 11 (2005), 5-12.
20. G. Guyatt, Preface, in: Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, G. Guyatt and D. Rennie, eds, AMA Press, Chicago, IL, 2002, p. xiv.
21. D.R. Zucker, C.H. Schmid, M.W. McIntosh, R.B. D’Agostino, H.P. Selker and J. Lau, Combining Single Patient (N of -1) Trials to Estimate Population Treatment Effects and to Evaluate Individual Patient Responses to Treatment, J Clin Epidemiol 50(4) (1997), 401-410.
22. S. Todd, A. Whitehead, N. Stallard and J. Whitehead, Interim analyses and sequential designs in phase III studies, J Clin Pharmacol 51, 394-399.
23. D.A. Berry, Bayesian Design & Analysis Of Drug & Device Trials. Presented to joint FDA/NIH Workshop on Can Bayesian approaches to studying new treatments improve regulatory decision making? On http://www.cfsan.fda.gov/-frf/bayesdl.html. Accessed on 1 March 2009.
24. P. Noguchi, Simple Complexity in an Evolving World: Rising to the Challenge. On http://74.125.77.132/search?q=cache:SLJxIAVjNs…+Noguchi+ppt+humility&hl=en&ct=clnk&cd=1&gl =be. Accessed on 1 March 2009.